Literature DB >> 18054127

The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia.

Heather F Gidding1, Margaret Warlow, C Raina MacIntyre, Josephine Backhouse, Gwendolyn L Gilbert, Helen E Quinn, Peter B McIntyre.   

Abstract

We compared the results of two national serosurveys in Australia to evaluate the impact of universal infant vaccination and school-based programs for adolescents. Immunity improved significantly overall, especially in 1-year-olds (40.0% versus 86%; p<0.0001); in adolescents it was significantly higher in regions with established school-based programs (56.6% versus 38.8%; p=0.0008). 6.1% of 1-59-year-olds were positive for HBcAb and 0.7% for HBsAg. We have demonstrated successful implementation of universal infant hepatitis B vaccination in Australia and that school-based programs for adolescents are effective. This experience should be applicable to low prevalence countries in northern Europe which have not implemented universal hepatitis B immunisation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18054127     DOI: 10.1016/j.vaccine.2007.07.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists.

Authors:  Fiona L Day; Emma Link; Karin Thursky; Danny Rischin
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

2.  Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B.

Authors:  Farzan Fahrtash-Bahin; Viraj C Kariyawasam; Timothy Gray; Karen Byth; Jacob George; Mark W Douglas
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

3.  Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model.

Authors:  Michael Kotiw; Megan Johnson; Manisha Pandey; Scott Fry; Stuart L Hazell; Hans J Netter; Michael F Good; Colleen Olive
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

4.  Correlates of susceptibility to hepatitis B among people who inject drugs in Sydney, Australia.

Authors:  Rachel M Deacon; Libby Topp; Handan Wand; Carolyn A Day; Craig Rodgers; Paul S Haber; Ingrid van Beek; Lisa Maher
Journal:  J Urban Health       Date:  2012-10       Impact factor: 3.671

5.  Evaluating the implementation of the 13-valent pneumococcal vaccine supplementary dose program in Australian primary health care settings.

Authors:  Kirsten F Ward; Marianne Trent; Brynley P Hull; Helen E Quinn; Aditi Dey; Robert I Menzies
Journal:  BMC Health Serv Res       Date:  2015-03-18       Impact factor: 2.655

6.  Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementation.

Authors:  H Theeten; V Hutse; K Hoppenbrouwers; P Beutels; P VAN Damme
Journal:  Epidemiol Infect       Date:  2013-05-21       Impact factor: 4.434

7.  Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population.

Authors:  Jane Davies; Shu Qin Li; Steven Y Tong; Rob W Baird; Miles Beaman; Geoff Higgins; Benjamin C Cowie; John R Condon; Joshua S Davis
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.